Logo image of CRDF

CARDIFF ONCOLOGY INC (CRDF) Stock Fundamental Analysis

NASDAQ:CRDF - Nasdaq - US14147L1089 - Common Stock - Currency: USD

2.44  0 (0%)

Premarket: 2.45 +0.01 (+0.41%)

Fundamental Rating

3

CRDF gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. While CRDF seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CRDF is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRDF has reported negative net income.
In the past year CRDF has reported a negative cash flow from operations.
In the past 5 years CRDF always reported negative net income.
CRDF had a negative operating cash flow in each of the past 5 years.
CRDF Yearly Net Income VS EBIT VS OCF VS FCFCRDF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

CRDF has a Return On Assets of -67.39%. This is in the lower half of the industry: CRDF underperforms 61.57% of its industry peers.
CRDF has a Return On Equity of -87.10%. This is comparable to the rest of the industry: CRDF outperforms 49.54% of its industry peers.
Industry RankSector Rank
ROA -67.39%
ROE -87.1%
ROIC N/A
ROA(3y)-43.63%
ROA(5y)-33.32%
ROE(3y)-50.23%
ROE(5y)-37.7%
ROIC(3y)N/A
ROIC(5y)N/A
CRDF Yearly ROA, ROE, ROICCRDF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

CRDF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDF Yearly Profit, Operating, Gross MarginsCRDF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

CRDF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRDF has been increased compared to 1 year ago.
Compared to 5 years ago, CRDF has more shares outstanding
CRDF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRDF Yearly Shares OutstandingCRDF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRDF Yearly Total Debt VS Total AssetsCRDF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -3.38, we must say that CRDF is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.38, CRDF is in line with its industry, outperforming 46.27% of the companies in the same industry.
CRDF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.38
ROIC/WACCN/A
WACC9.62%
CRDF Yearly LT Debt VS Equity VS FCFCRDF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CRDF has a Current Ratio of 4.42. This indicates that CRDF is financially healthy and has no problem in meeting its short term obligations.
CRDF's Current ratio of 4.42 is in line compared to the rest of the industry. CRDF outperforms 49.36% of its industry peers.
A Quick Ratio of 4.42 indicates that CRDF has no problem at all paying its short term obligations.
CRDF has a Quick ratio (4.42) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.42
Quick Ratio 4.42
CRDF Yearly Current Assets VS Current LiabilitesCRDF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.30% over the past year.
The Revenue for CRDF has decreased by -17.77% in the past year. This is quite bad
CRDF shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.27% yearly.
EPS 1Y (TTM)3.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
Revenue 1Y (TTM)-17.77%
Revenue growth 3Y23.8%
Revenue growth 5Y23.27%
Sales Q2Q%-25.77%

3.2 Future

CRDF is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.01% yearly.
Based on estimates for the next years, CRDF will show a very strong growth in Revenue. The Revenue will grow by 178.11% on average per year.
EPS Next Y14.64%
EPS Next 2Y0.23%
EPS Next 3Y-8.44%
EPS Next 5Y-11.01%
Revenue Next Year-32.46%
Revenue Next 2Y-27.6%
Revenue Next 3Y-45.28%
Revenue Next 5Y178.11%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRDF Yearly Revenue VS EstimatesCRDF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
CRDF Yearly EPS VS EstimatesCRDF Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRDF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRDF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDF Price Earnings VS Forward Price EarningsCRDF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDF Per share dataCRDF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

CRDF's earnings are expected to decrease with -8.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.23%
EPS Next 3Y-8.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRDF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIFF ONCOLOGY INC

NASDAQ:CRDF (8/15/2025, 8:13:18 PM)

Premarket: 2.45 +0.01 (+0.41%)

2.44

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners46%
Inst Owner Change-10.67%
Ins Owners2.01%
Ins Owner Change18.14%
Market Cap162.33M
Analysts82.86
Price Target11.99 (391.39%)
Short Float %30.38%
Short Ratio13.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.1%
Min EPS beat(2)-6.95%
Max EPS beat(2)-5.25%
EPS beat(4)2
Avg EPS beat(4)1.94%
Min EPS beat(4)-6.95%
Max EPS beat(4)10.75%
EPS beat(8)5
Avg EPS beat(8)8.47%
EPS beat(12)8
Avg EPS beat(12)8.92%
EPS beat(16)10
Avg EPS beat(16)4.89%
Revenue beat(2)2
Avg Revenue beat(2)11.23%
Min Revenue beat(2)10.82%
Max Revenue beat(2)11.65%
Revenue beat(4)4
Avg Revenue beat(4)45.47%
Min Revenue beat(4)10.82%
Max Revenue beat(4)102.21%
Revenue beat(8)8
Avg Revenue beat(8)137.95%
Revenue beat(12)12
Avg Revenue beat(12)113.76%
Revenue beat(16)16
Avg Revenue beat(16)115.05%
PT rev (1m)-18.4%
PT rev (3m)-17.25%
EPS NQ rev (1m)-3.15%
EPS NQ rev (3m)11.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)20.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 297.31
P/FCF N/A
P/OCF N/A
P/B 2.77
P/tB 2.77
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0.01
BVpS0.88
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.39%
ROE -87.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.63%
ROA(5y)-33.32%
ROE(3y)-50.23%
ROE(5y)-37.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.77%
Cap/Sales 4.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.42
Quick Ratio 4.42
Altman-Z -3.38
F-Score2
WACC9.62%
ROIC/WACCN/A
Cap/Depr(3y)195.62%
Cap/Depr(5y)135.64%
Cap/Sales(3y)129.98%
Cap/Sales(5y)101.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
EPS Next Y14.64%
EPS Next 2Y0.23%
EPS Next 3Y-8.44%
EPS Next 5Y-11.01%
Revenue 1Y (TTM)-17.77%
Revenue growth 3Y23.8%
Revenue growth 5Y23.27%
Sales Q2Q%-25.77%
Revenue Next Year-32.46%
Revenue Next 2Y-27.6%
Revenue Next 3Y-45.28%
Revenue Next 5Y178.11%
EBIT growth 1Y-21.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.08%
OCF growth 3YN/A
OCF growth 5YN/A